Patents by Inventor Jeffrey Dean Kahl

Jeffrey Dean Kahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds as pharmaceutical agents
    Patent number: 7902237
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of the disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Grant
    Filed: August 9, 2005
    Date of Patent: March 8, 2011
    Assignee: Exelixis, Inc.
    Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl
  • Heterocyclic Compounds As Pharmaceutical Agents
    Publication number: 20080132519
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of the disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Application
    Filed: August 9, 2005
    Publication date: June 5, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl
  • Heterocyclic modulators of nuclear receptors
    Publication number: 20040180942
    Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
    Type: Application
    Filed: November 18, 2003
    Publication date: September 16, 2004
    Applicant: X-Ceptor Therapeutics, Inc.
    Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl, Tie-Lin Wang
  • Heterocyclic modulators of nuclear receptors
    Patent number: 6696473
    Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: February 24, 2004
    Assignee: X-Ceptor Therapeutics, Inc.
    Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl, Tie-Lin Wang
  • Heterocyclic modulators of nuclear receptors
    Publication number: 20030212111
    Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
    Type: Application
    Filed: December 20, 2002
    Publication date: November 13, 2003
    Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl, Tie-Lin Wang